ORIC PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
ORIC PHARMACEUTICALS, INC. (ORIC) had Debt Securities, Available-for-sale, Amortized Cost of $90.99 million as of 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-08-10
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $90.99M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $173.92M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $215.19M.
- 2020-09-30: Debt Securities, Available-for-sale, Amortized Cost $124.61M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-06-30 | $90.99M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $173.92M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $215.19M 10-Q · filed 2021-08-10 |
| 2020-09-30 | $124.61M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |